home / stock / crvs / crvs news


CRVS News and Press, Corvus Pharmaceuticals Inc. From 10/05/21

Stock Information

Company Name: Corvus Pharmaceuticals Inc.
Stock Symbol: CRVS
Market: NASDAQ
Website: corvuspharma.com

Menu

CRVS CRVS Quote CRVS Short CRVS News CRVS Articles CRVS Message Board
Get CRVS Alerts

News, Short Squeeze, Breakout and More Instantly...

CRVS - 2 Biotech Stocks That Surged More Than 100% in September

The biotech industry continues to play a crucial role in developing solutions to treat critical ailments. In addition, the demand for biotech solutions is also high across other sectors such as food and agriculture. So, biotech stocks such as Leap Therapeutics (LPTX) and Corvus Pharmaceutical...

CRVS - CRVS, ENG and LIZI among mid-day movers

Gainers: Alzamend Neuro (NASDAQ:ALZN) +44%. Farmmi (NASDAQ:FAMI) +31%. Paltalk (NASDAQ:PALT) +29%. Onion Global (NYSE:OG) +27%. Progenity (NASDAQ:PROG) +23%. China Online Education (NYSE:COE) +17%. Meten Holding (NASDAQ:METX) +16%. Achilles Therapeutics (NASDAQ:ACHL) +13%. Crown Ele...

CRVS - Alzamend Neuro, Progenity leads healthcare gainers; Corvus Pharmaceuticals, NuCana among major losers

Gainers: Alzamend Neuro (NASDAQ:ALZN) +52%, Progenity (NASDAQ:PROG) +18%, OptimizeRx (NASDAQ:OPRX) +15%, Atea Pharmaceuticals (NASDAQ:AVIR) +14%, Perrigo (NYSE:PRGO) +11%. Losers: Corvus Pharmaceuticals (NASDAQ:CRVS) -15%, NuCana (NASDAQ:NCNA)...

CRVS - Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells

Palm Beach, FL – September 28, 2021 – FinancialNewsMedia.com News Commentary More than 100 companies have rushed into vaccine development against COVID-19 as the U.S. government pushes for a vaccine rollout at “warp speed” — possibly by the end...

CRVS - FEIM, LILM, DOCU and IMRX among after hours movers

Gainers: FEIM +24.6%. LILM +6.5%. CNXC +6.0%. SCPS +5.5%. SGMS +4.3%. Losers: DOCU -6.1%. IMRX -5.0%. HIBB -1.7%. CRVS -1.6%. VG -1.5%. For further details see: FEIM, LILM, DOCU and IMRX among after hours movers

CRVS - Is Corvus Pharmaceuticals a Good Healthcare Stock to Add to Your Portfolio?

Corvus Pharmaceuticals (CRVS) has been making headway on several developments in the immuno-oncology therapies space, which sent its shares soaring to their 52-week high of $9.54 on September 21. However, the stock’s price has since declined on profit-taking. So, let’s find out ...

CRVS - Corvus Pharmaceuticals: More Than A CD73 Sympathy Play

Shares rose by 135% on Friday alone, but as of Wednesday have still lost half their value since 2017. Additionally, current enterprise value is still around $260 million. ESMO data release for AstraZeneca's COAST study in lung cancer has potentially validated CD73 drug class, of which...

CRVS - Why Corvus Pharmaceuticals Stock Is Down Today

Shares of Corvus Pharmaceuticals (NASDAQ: CRVS) , a clinical-stage biotech, were down by 11.7% as of 2:43 p.m. EDT on Wednesday. Although the company announced the pre-print of results from its discontinued COVID-19 study evaluating the anti-CD73 antibody mupadolimab this morning, t...

CRVS - Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Corvus stock has made spectacular gains across the past week, rising from a price of $2.3 to $8.5 - a 270% gain. Last week, AstraZeneca's Oleclumab - an anti-CD73 therapy - substantially improved the risk of death in combo with IMFINZI in NSCLC. Corvus' Mupadolimab is an anti-CD73...

CRVS - RWLK, CRVS and AEMD among mid-day movers

Gainers: Marin Software MRIN +58%. Aethlon Medical (NASDAQ:AEMD) +33%. WiMi Hologram WIMI +32%. Onconova Therapeutics ONTX +25%. Dynavax DVAX +26%. Gaotu Techedu GOTU +18%. Candel (NASDAQ:CADL) +19%. Ramaco Resources (NASDAQ:METC) +16%. Celestica CLS +16%. Arqit ...

Previous 10 Next 10